Email this article Current approaches to the diagnosis and treatment of postmenopausal osteoporosis
- Authors: Baranova I.A.1, Baranova IA1
-
Affiliations:
- Issue: Vol 81, No 10 (2009)
- Pages: 56-60
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30527
- ID: 30527
Cite item
Full Text
Abstract
Postmenopausal osteoporosis (OP) is a disease afflicting every three women above 50 years of age. The sociomedical significance of OP is determined by the development of fracture in minimal injuries resulting in disability and, occasionally, death. The review presents a new management strategy described in the European and Russian guidelines. Particular emphasis is laid on the early identification and treatment of patients at high risk for fractures. The current requirements for drugs used to treat OP are described, by using as an example strontium ranelate, one of the first-line agents for the treatment of postmenopausal OP.
References
- Cummings S. R., Melton L. J. III. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359 (9319): 1761- 1767.
- Kanis J. A., Oden A., Johnell O. et al. The components of excess mortality after hip fracture. Bone 2003; 32 (5): 468-473.
- Johnell O., Kanis J. A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 2006; 17 (12): 1726-1733.
- Kanis J. A., Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos. Int. 2005; 16: 229-236.
- Kanis J. A., Burlet N., Cooper C. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 2008; 19 (4): 399-428.
- Лесняк О. М., Беневоленская Л. И. (ред.). Остеопороз. М.: ГЭОТАР-Медиа; 2009.
- Reginster J. Y., Deroisy R., Dougados M. et al. Prevention of early postmenopausal bone loss by strontium ranelate: a randomized, two-year, double-blind, dose-ranging, placebo-controlled trial. Osteoporos. Int. 2002; 13 (12): 925-931.
- Meunier P. J., Slosman D. O., Delmas P. D. et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. 2002; 87 (5): 2060-2066.
- Meunier P. J., Roux C., Seeman E. et al. The effect of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 2004; 350 (5): 459-468.
- Reginster J. Y., Seeman E., De Vernejoul M. C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrinol. 2005; 90 (5): 2816-2822.
- Reginster J. Y., Felsenberg D., Boonen S. et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthr. and Rheum. 2008; 58 (6): 1687-1695.
- Neuprez A., Hiligsmann M., Scholtissen S. et al. Strontium ranelate: the first agent of new therapeutic class in osteoporosis. Adv. Ther. 2008; 25 (12): 1235-1256.
- Bruyere O., Roux C., Detilleux J. et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J. Clin. Endocrinol. 2007; 92 (8): 3076-3081.
- Marquis P., Roux C., de la Loge C. et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos. Int. 2008; 19 (4): 503-510.
- Рожинская Л. Я., Беневоленская Л. И., Родионова С. С. и др. Исследование эффективности и безопасности лечения Бивалосом (стронция ранелат) постменопаузального остеопороза: результаты российского многоцентрового исследования. Тер. арх. 2008; 80 (5): 47-52.
Supplementary files
